KR100884417B1 - 호중구의 ｉｌ-8-유도된 화학주성의 저해에 유용한 아미드 - Google Patents

호중구의 ｉｌ-8-유도된 화학주성의 저해에 유용한 아미드 Download PDF

Info

Publication number
KR100884417B1
KR100884417B1 KR1020027009836A KR20027009836A KR100884417B1 KR 100884417 B1 KR100884417 B1 KR 100884417B1 KR 1020027009836 A KR1020027009836 A KR 1020027009836A KR 20027009836 A KR20027009836 A KR 20027009836A KR 100884417 B1 KR100884417 B1 KR 100884417B1
Authority
KR
South Korea
Prior art keywords
phenyl
formula
propionamide
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020027009836A
Other languages
English (en)
Korean (ko)
Other versions
KR20020073194A (ko
Inventor
마르셀로 알레그레티
리카르도 베르티니
비짜르리 친지아
빌마 사바티니
지안프란코 카셀리
마리아칸디다 체스타
카르멜로 간돌피
프란세스코 콜로타
Original Assignee
돔페 파르마 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 돔페 파르마 에스.피.에이. filed Critical 돔페 파르마 에스.피.에이.
Publication of KR20020073194A publication Critical patent/KR20020073194A/ko
Application granted granted Critical
Publication of KR100884417B1 publication Critical patent/KR100884417B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020027009836A 2000-02-11 2001-02-06 호중구의 ｉｌ-8-유도된 화학주성의 저해에 유용한 아미드 Expired - Fee Related KR100884417B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2000A000227 2000-02-11
IT2000MI000227A IT1317826B1 (it) 2000-02-11 2000-02-11 Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.

Publications (2)

Publication Number Publication Date
KR20020073194A KR20020073194A (ko) 2002-09-19
KR100884417B1 true KR100884417B1 (ko) 2009-02-19

Family

ID=11443980

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020027009836A Expired - Fee Related KR100884417B1 (ko) 2000-02-11 2001-02-06 호중구의 ｉｌ-8-유도된 화학주성의 저해에 유용한 아미드

Country Status (27)

Country Link
US (1) US7705050B2 (enExample)
EP (1) EP1255726B1 (enExample)
JP (1) JP4937479B2 (enExample)
KR (1) KR100884417B1 (enExample)
CN (1) CN100513386C (enExample)
AT (1) ATE448195T1 (enExample)
AU (2) AU4412501A (enExample)
BR (2) BRPI0108152B1 (enExample)
CA (1) CA2396937C (enExample)
CY (1) CY1109780T1 (enExample)
CZ (1) CZ302945B6 (enExample)
DE (1) DE60140429D1 (enExample)
DK (1) DK1255726T3 (enExample)
EE (1) EE05284B1 (enExample)
ES (1) ES2336301T3 (enExample)
HU (1) HU229447B1 (enExample)
IL (1) IL150523A0 (enExample)
IT (1) IT1317826B1 (enExample)
MX (1) MXPA02007714A (enExample)
NO (1) NO331460B1 (enExample)
NZ (1) NZ519925A (enExample)
PL (1) PL207126B1 (enExample)
PT (1) PT1255726E (enExample)
RU (1) RU2273630C2 (enExample)
SI (1) SI1255726T1 (enExample)
SK (1) SK287224B6 (enExample)
WO (1) WO2001058852A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230093944A (ko) 2021-12-20 2023-06-27 주식회사 우아한형제들 자율이동장치의 최적 주행 경로를 결정하기 위한 방법 및 이를 수행하는 컴퓨팅 시스템

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318466B1 (it) * 2000-04-14 2003-08-25 Dompe Spa Ammidi di acidi r-2-(amminoaril)-propionici, utili nella prevenzionedell'attivazione leucocitaria.
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
ITMI20010395A1 (it) 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
ITMI20012434A1 (it) 2001-11-20 2003-05-20 Dompe Spa Acidi 2-aril-propionici e composizioni farmaceutiche che li contengono
DE60323264D1 (de) * 2002-12-10 2008-10-09 Dompe Spa Chirale arylketone zur behandlung neutrophil-abhängiger entzündungskrankheiten
JP5208411B2 (ja) 2003-02-06 2013-06-12 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ ２−アリール−酢酸、その誘導体、及びそれらを含有する医薬組成物
EP1457485A1 (en) * 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
PT1663960E (pt) 2003-09-25 2011-12-16 Dompe Spa Amidinas e os seus derivados e composições farmacêuticas que os contêm
ATE444286T1 (de) * 2004-03-23 2009-10-15 Dompe Pha R Ma Spa Res & Mfg 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
AU2005315591B2 (en) * 2004-12-15 2011-03-17 Dompe' Farmaceutici S.P.A. 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
JP2008528546A (ja) * 2005-01-25 2008-07-31 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ ２−アリールプロピオン酸誘導体の代謝産物及びそれを含有する医薬組成物
PT2024329E (pt) * 2006-05-18 2013-11-04 Dompe Spa (2r)-2-[(4-sulfonil)aminofenil]propanamidas e composições farmacêuticas que as contenham
AU2007264114A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New CXCR2 inhibitors
JP5232144B2 (ja) 2006-06-28 2013-07-10 サノフイ Ｃｘｃｒ２阻害剤
EP2041072B1 (en) 2006-06-28 2013-09-11 Sanofi Cxcr2 antagonists
EP2041073B1 (en) * 2006-06-30 2016-07-27 Sanofi Cxcr2 inhibitors
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
ES2559781T3 (es) * 2006-08-08 2016-02-15 Techfields Biochem Co. Ltd Profármacos de ácidos aril- y heteroarilacéticos solubles en agua y con carga positiva con una tasa de penetración en piel muy rápida
CN103772258B (zh) * 2006-08-08 2016-09-28 于崇曦 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药
CN103772259B (zh) * 2006-08-08 2016-08-31 于崇曦 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药
CA2660814C (en) * 2006-08-15 2017-07-18 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
KR20210103586A (ko) 2007-06-04 2021-08-23 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(ｎｓａｉａ) 약물전구체 및 이들의 새로운 의약적 용도
UA105759C2 (uk) * 2007-10-08 2014-06-25 Ммв Медісінс Фор Мелеріе Венче 2,4-діамінопіримідини, фармацевтична композиція, що їх містить, та спосіб лікування малярії
JP2011507909A (ja) 2007-12-20 2011-03-10 エンビボ ファーマシューティカルズ インコーポレイテッド 四置換ベンゼン
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
MX380878B (es) 2008-12-04 2025-03-12 Chongxi Yu Composiciones de alta penetracion y sus aplicaciones.
CN105360132A (zh) * 2010-11-03 2016-03-02 陶氏益农公司 杀虫组合物和与其相关的方法
CN103159674A (zh) * 2013-04-03 2013-06-19 苏州安诺生物医药技术有限公司 2-苯烷酰胺类化合物及其制备方法、药物组合物和用途
US11850220B2 (en) * 2020-05-19 2023-12-26 Augusta University Research Institute, Inc. Synthesis of ibuprofen hybrid conjugates as anti-inflammatory and analgesic agents
CN117105822A (zh) * 2022-12-26 2023-11-24 杭州澳赛诺生物科技有限公司 一种(r)-3-(叔丁氧碳基)氨基-2-甲基丙酸合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002903A1 (en) * 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54141754A (en) * 1978-04-26 1979-11-05 Takayuki Shioiri Manufacture of 22*33benzoylphenyl*propionic acid
IT1193955B (it) * 1980-07-22 1988-08-31 Real Di Alberto Reiner S A S Derivati ammidici dell'acido p-isobutilfenilpropionico, procedimento per la loro preparazione e relative composizioni farmaceutici
IT1203605B (it) * 1985-04-18 1989-02-15 Alfa Chem Ital Processo per la risoluzione ottica di miscigli racemi di acidi e naftilpropionici
GB8719886D0 (en) 1987-08-22 1987-09-30 British Petroleum Co Plc Carboxylic acid esters/acids
JPH0791216B2 (ja) * 1988-10-10 1995-10-04 日本石油化学株式会社 α−（３−（１−フエニルエチル）フェニル）プロピオン酸
AU4682193A (en) * 1992-07-29 1994-03-03 Merck & Co., Inc. Dexibuprofen/antacid/simethicone combinations
EP0618223A3 (en) 1993-03-08 1996-06-12 Sandoz Ltd Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents.
JPH07149646A (ja) * 1993-11-29 1995-06-13 Asahi Chem Ind Co Ltd ケミカルメディエーター遊離抑制剤
DE69607974T2 (de) * 1995-05-31 2000-10-05 Ihara Chemical Industry Co., Ltd. Phenylalkanamid-derivate und land- und gartenbauwirtschaftliche baterizide
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002903A1 (en) * 1998-07-10 2000-01-20 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230093944A (ko) 2021-12-20 2023-06-27 주식회사 우아한형제들 자율이동장치의 최적 주행 경로를 결정하기 위한 방법 및 이를 수행하는 컴퓨팅 시스템

Also Published As

Publication number Publication date
HUP0301576A3 (en) 2004-10-28
NZ519925A (en) 2004-12-24
SK287224B6 (sk) 2010-03-08
ITMI20000227A1 (it) 2001-08-11
PL362506A1 (en) 2004-11-02
EE05284B1 (et) 2010-04-15
AU4412501A (en) 2001-08-20
WO2001058852A3 (en) 2002-03-14
WO2001058852A2 (en) 2001-08-16
CN100513386C (zh) 2009-07-15
NO20023817L (no) 2002-08-12
CZ20022728A3 (cs) 2003-01-15
CN1479715A (zh) 2004-03-03
PL207126B1 (pl) 2010-11-30
RU2002124136A (ru) 2004-01-10
BR0108152A (pt) 2003-03-25
DK1255726T3 (da) 2010-03-22
JP2003522750A (ja) 2003-07-29
ITMI20000227A0 (it) 2000-02-11
NO331460B1 (no) 2012-01-09
ES2336301T3 (es) 2010-04-12
NO20023817D0 (no) 2002-08-12
HUP0301576A2 (hu) 2003-11-28
HU229447B1 (en) 2013-12-30
MXPA02007714A (es) 2002-10-23
RU2273630C2 (ru) 2006-04-10
CZ302945B6 (cs) 2012-01-25
IL150523A0 (en) 2003-02-12
CA2396937C (en) 2011-09-13
DE60140429D1 (de) 2009-12-24
EP1255726B1 (en) 2009-11-11
AU2001244125B2 (en) 2006-11-09
SK11412002A3 (sk) 2003-01-09
US7705050B2 (en) 2010-04-27
JP4937479B2 (ja) 2012-05-23
US20040181073A1 (en) 2004-09-16
SI1255726T1 (sl) 2010-03-31
CA2396937A1 (en) 2001-08-16
CY1109780T1 (el) 2014-09-10
PT1255726E (pt) 2010-02-11
ATE448195T1 (de) 2009-11-15
HK1062675A1 (zh) 2004-11-19
BRPI0108152B1 (pt) 2017-09-26
EE200200441A (et) 2003-12-15
IT1317826B1 (it) 2003-07-15
EP1255726A2 (en) 2002-11-13
KR20020073194A (ko) 2002-09-19

Similar Documents

Publication Publication Date Title
KR100884417B1 (ko) 호중구의 ｉｌ-8-유도된 화학주성의 저해에 유용한 아미드
KR100890680B1 (ko) 다핵세포와 단핵세포의 주화성 저해물질인ｒ-2-아릴-프로피온산의 오메가-아미노알킬아마이드
JPH08508027A (ja) 金属タンパク加水分解酵素阻害剤である天然アミノ酸誘導体
ES2393589T3 (es) Ácidos 2-arilpropiónicos y composiciones farmacéuticas que los contienen
KR101291483B1 (ko) 2-아릴프로피온산 유도체 및 이들을 함유하는 제약학적조성물
RU2268263C2 (ru) Амиды r-2-(аминоарил) пропионовых кислот для применения при предотвращении активации лейкоцитов
HK1062675B (en) Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils
AU2001246539A1 (en) Amides of R-2-(aminoaryl)-propionic acids for use in the prevention of leucocyte activation

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20130130

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20140122

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20150129

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20160129

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190212

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190212